Opportunities for milk and milk-related systems as ‘new’ low-cost excipient drug delivery materials
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Opportunities for milk and milk-related systems as ‘new’ low-cost excipient drug delivery materials. / Salim, Malinda; Eason, Thomas; Boyd, Ben J.
I: Advanced Drug Delivery Reviews, Bind 183, 114139, 2022.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Opportunities for milk and milk-related systems as ‘new’ low-cost excipient drug delivery materials
AU - Salim, Malinda
AU - Eason, Thomas
AU - Boyd, Ben J.
N1 - Funding Information: TE is supported by a PhD stipend top up by Quotient Sciences, UK. BB is supported by a Novo Nordisk Foundation Laureate Research Fellowship. Malinda Salim is supported by an ARC Linkage Projects grant (LP180101147) and was supported by the Bill and Melinda Gates Foundation (OPP1160404) for our work in the field of this review. BB especially would like to thank Frank Szoka for great support throughout his career, for introducing him to Red Bull as an experiment-enhancing nutrition source and for some outstanding discussions in Somona and a lift to UC Davis that led indirectly to funding of much of the cited work through the Bill and Melinda Gates Foundation on milk and infant formula as a drug delivery system. Publisher Copyright: © 2022 The Author(s)
PY - 2022
Y1 - 2022
N2 - Milk is well recognised as an amazing delivery system for essential lipids, poorly soluble nutrients, sugars, amino acids and delivery of critical biological molecules to sustain the infant and adult alike. It is also a safe and abundant resource with potential to act as a low-cost material for formulation of medicines, especially for paediatric patients and those in low economy settings. However, its use in low cost formulations has never developed beyond preclinical evaluation. Reasons for this are several-fold including variable composition and therefore regulatory challenges, as well as a lack of clear understanding around when milk or milk-related materials like infant formula could best be deployed by linking drug properties with excipient composition attributes, especially when taking digestion into account. This review collects the current understanding around these issues. It is apparent from the evolving understanding that while milk may be a bridge too far for translation as an excipient, infant formula is positioned to play a key role in the future because, as a powder-based excipient, it has the performance benefits of milk powder together with the controlled specifications during manufacture and versatility of application to function as a low cost lipid excipient to enable potential translation for the oral delivery of poorly water soluble drugs for key populations including paediatrics and low economy medicines.
AB - Milk is well recognised as an amazing delivery system for essential lipids, poorly soluble nutrients, sugars, amino acids and delivery of critical biological molecules to sustain the infant and adult alike. It is also a safe and abundant resource with potential to act as a low-cost material for formulation of medicines, especially for paediatric patients and those in low economy settings. However, its use in low cost formulations has never developed beyond preclinical evaluation. Reasons for this are several-fold including variable composition and therefore regulatory challenges, as well as a lack of clear understanding around when milk or milk-related materials like infant formula could best be deployed by linking drug properties with excipient composition attributes, especially when taking digestion into account. This review collects the current understanding around these issues. It is apparent from the evolving understanding that while milk may be a bridge too far for translation as an excipient, infant formula is positioned to play a key role in the future because, as a powder-based excipient, it has the performance benefits of milk powder together with the controlled specifications during manufacture and versatility of application to function as a low cost lipid excipient to enable potential translation for the oral delivery of poorly water soluble drugs for key populations including paediatrics and low economy medicines.
KW - Digestion
KW - Formulation
KW - Infant formula
KW - Milk
KW - Poorly water-soluble drug
U2 - 10.1016/j.addr.2022.114139
DO - 10.1016/j.addr.2022.114139
M3 - Review
C2 - 35143892
AN - SCOPUS:85126127547
VL - 183
JO - Advanced Drug Delivery Reviews
JF - Advanced Drug Delivery Reviews
SN - 0169-409X
M1 - 114139
ER -
ID: 302372633